Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.
Auteurs : Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, DHondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F Année : 2021 Journal : Acta Oncol
Leukemia Inhibitory Factor: A Potential Biomarker and Therapeutic Target in Pancreatic Cancer.
Auteurs : Wrona E, Potemski P, Sclafani F, Borowiec M Année : 2021 Journal : Arch Immunol Ther Exp (Warsz)
Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials.
Auteurs : Giunta EF, Bregni G, Hendlisz A, Sclafani F Année : 2021 Journal : Curr Opin Oncol
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Auteurs : Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali MA, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F Année : 2021 Journal : Cancer Treat Rev
Radioembolization for metastatic colorectal cancer: towards maturity, at last?
Auteurs : Hendlisz A, Sclafani F Année : 2021 Journal : Curr Opin Oncol